Separate trials ask separate questions
A trial begins with a question, a group of participants and a comparison. Its result belongs to all three. The STEP 1 injection trial involved adults with obesity, or overweight and a weight-related condition, without diabetes. The PIONEER 1 oral trial involved adults with type 2 diabetes. Treating their results as a direct contest would erase a basic difference in the people studied.
Placebo means a dummy treatment used as a comparison. Randomization means assigning treatment by chance, which helps reduce differences between groups within a trial. These methods strengthen a comparison inside that study. They do not make participants in separate trials identical or turn all formulations into equivalents.
STEP and PIONEER are study-program names, not interchangeable labels for semaglutide research. The route, formulation, purpose and period measured still need to accompany a result. The ingredient article explains why the oral formulation’s absorption helper is part of the medicine being tested.

Oral evidence remains evidence for its formulation
PIONEER 1 reported blood-sugar and weight improvements with oral semaglutide compared with placebo in type 2 diabetes. The formulation was integral to the study. A tablet is more than its active ingredient considered in isolation; its other ingredients help determine how the active ingredient enters the body.
The current Wegovy prescribing information also distinguishes tablet and injection data. A label records the evidence and approved uses of particular products. The existence of evidence for both forms does not establish that a person can choose between them by comparing headline percentages from separate trials.
A direct comparison changes the question
SURMOUNT-5 compared tirzepatide with semaglutide directly in adults with obesity. The trial was open-label, meaning participants and researchers knew which treatment had been assigned. Tirzepatide and semaglutide are different active ingredients, so this is not a comparison of two semaglutide forms.
The paper’s identifier, NEJMoa2416394, helps locate the source. The reference page keeps that identifier and the commonly searched figures beside the study description. A direct comparison strengthens what can be said about those assigned treatments, while leaving questions about other populations and individual decisions unresolved.
After treatment and study support ended
In the STEP 1 extension, a smaller group from the original injection study was followed after semaglutide and structured lifestyle support ended. Much of the prior weight loss returned on average. Both changes matter; the design cannot tell us what every possible kind of later support would have achieved.
The participants in that follow-up were a subset, not the entire original trial. An extension can add useful observations while having a narrower scope. Weight regain in a study describes an observed outcome. It does not establish a moral judgment about effort, nor does it establish a universal duration of treatment.

Continuing was tested in another design
In STEP 4, participants first shared an initial semaglutide treatment period. Some then continued semaglutide and others switched to placebo. Continued treatment led to further average weight loss, while the placebo group regained weight.
That later comparison began after the common treatment period. Its baseline, the point from which change was measured, was therefore different from initial trial entry. People who reached the later stage were also the population for that question. Ignoring either point makes the result sound broader than it is.
What the studies leave open
None of these trials establishes a home-made stopping plan, an oral-to-injection conversion or the performance of every compounded preparation. FDA distinguishes compounded drugs from approved products. An ingredient shared across preparations is not a substitute for evidence about the preparation itself.
The weight article follows the outcome measurements, and the effects article places benefits beside adverse reactions. Reading the comparison, population and time point together keeps a research result useful without making it carry a treatment decision it was never designed to make.